Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 579,339,648
  • Shares Outstanding, K 2,409,899
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 30,550 M
  • EBITDA $ 38,053 M
  • 60-Month Beta 0.34
  • Price/Sales 6.13
  • Price/Cash Flow 16.97
  • Price/Book 7.08

Options Overview Details

View History
  • Implied Volatility 27.46% (+0.64%)
  • Historical Volatility 15.77%
  • IV Percentile 98%
  • IV Rank 66.14%
  • IV High 35.15% on 04/08/25
  • IV Low 12.42% on 07/24/25
  • Expected Move (DTE 4) 5.19 (2.13%)
  • Put/Call Vol Ratio 0.66
  • Today's Volume 15,581
  • Volume Avg (30-Day) 46,703
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 373,802
  • Open Int (30-Day) 381,246
  • Expected Range 237.87 to 248.24

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 26 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 2.69
  • Number of Estimates 8
  • High Estimate 2.85
  • Low Estimate 2.41
  • Prior Year 2.77
  • Growth Rate Est. (year over year) -2.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
235.43 +2.99%
on 03/06/26
251.71 -3.67%
on 03/02/26
+3.84 (+1.61%)
since 02/09/26
3-Month
200.18 +21.13%
on 12/10/25
251.71 -3.67%
on 03/02/26
+42.52 (+21.26%)
since 12/09/25
52-Week
141.50 +71.36%
on 04/09/25
251.71 -3.67%
on 03/02/26
+75.79 (+45.47%)
since 03/07/25

Most Recent Stories

More News
Johnson & Johnson Announces U.S. FDA Approval of TECVAYLI® plus DARZALEX FASPRO® for Relapsed/Refractory Multiple Myeloma, Offering a Potential New Standard of Care as Early as Second Line

Approval based on unprecedented Phase 3 data demonstrating statistically significant improvements in progression – free survival and overall survival versus standard of care regimens

JNJ : 242.59 (+0.91%)
Anxiety Treatment Boom: GAD Therapies Poised for Multi-Billion Dollar Expansion

EQNX::TICKER_START (NNASDAQ:HELP),(CBOE:HELP),(NASDAQ:ACHC),(NYSE:JNJ),(NASDAQ:BWAY),(NASDAQ:AIFF) EQNX::TICKER_END

HELP : 5.52 (+5.14%)
BWAY : 12.66 (+2.59%)
ACHC : 24.71 (-3.55%)
AIFF : 1.6700 (-9.73%)
JNJ : 242.59 (+0.91%)
When Fear Hits the Stock Market, Where Can Investors Find Safety?

Our senior market strategist takes a look at traditionally defensive sectors to find opportunities in the current market uncertainty.

$VIX : 25.50 (-13.53%)
JNJ : 242.59 (+0.91%)
CAH : 222.28 (+2.07%)
MRNA : 55.74 (+6.13%)
Johnson & Johnson therapy nipocalimab granted U.S. FDA Fast Track designation in systemic lupus erythematosus (SLE)

Fast Track designation reflects the unmet need in this serious disease and enables the potential for an accelerated FDA review timeline

JNJ : 242.59 (+0.91%)
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 14 th to review first-quarter results....

JNJ : 242.59 (+0.91%)
Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer

Combination demonstrates deep PSA responses and favorable safety profile with plans to advance into Phase 3

JNJ : 242.59 (+0.91%)
A Decade From Now, You'll Regret Not Buying This 1 Small-Cap Stock

The best long-term winners often start small.

SYK : 365.92 (+0.37%)
$SPX : 6,795.99 (+0.83%)
JNJ : 242.59 (+0.91%)
MDT : 91.34 (+0.48%)
ISRG : 493.56 (+0.69%)
ATEC : 12.87 (+5.23%)
Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Data from the pivotal ENERGY trial showed IMAAVY ® produced a rapid and durable hemoglobin response a in wAIHA

JNJ : 242.59 (+0.91%)
Is Johnson & Johnson Stock Outperforming the Nasdaq?

Though Johnson & Johnson has outperformed the broader Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

$NASX : 22,695.95 (+1.38%)
JNJ : 242.59 (+0.91%)
LLY : 1,008.39 (+1.82%)
Is Eli Lilly Stock Underperforming the S&P 500?

Eli Lilly has recently trailed the S&P 500 Index, though analysts remain confident in its longer-term trajectory.

$SPX : 6,795.99 (+0.83%)
JNJ : 242.59 (+0.91%)
LLY : 1,008.39 (+1.82%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 247.68
2nd Resistance Point 244.23
1st Resistance Point 242.32
Last Price 242.59
1st Support Level 236.96
2nd Support Level 233.51
3rd Support Level 231.60

See More

52-Week High 251.71
Last Price 242.59
Fibonacci 61.8% 209.61
Fibonacci 50% 196.61
Fibonacci 38.2% 183.60
52-Week Low 141.50

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar